JP2021155415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021155415A5 JP2021155415A5 JP2021049350A JP2021049350A JP2021155415A5 JP 2021155415 A5 JP2021155415 A5 JP 2021155415A5 JP 2021049350 A JP2021049350 A JP 2021049350A JP 2021049350 A JP2021049350 A JP 2021049350A JP 2021155415 A5 JP2021155415 A5 JP 2021155415A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fluorobenzyl
- pyridin
- oxy
- cyano
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025083688A JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000787P | 2020-03-27 | 2020-03-27 | |
| US63/000787 | 2020-03-27 | ||
| US202063126113P | 2020-12-16 | 2020-12-16 | |
| US63/126113 | 2020-12-16 | ||
| US202163135870P | 2021-01-11 | 2021-01-11 | |
| US63/135870 | 2021-01-11 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083688A Division JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021155415A JP2021155415A (ja) | 2021-10-07 |
| JP2021155415A5 true JP2021155415A5 (enExample) | 2024-03-21 |
Family
ID=75252595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021049350A Pending JP2021155415A (ja) | 2020-03-27 | 2021-03-24 | ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
| JP2025083688A Pending JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025083688A Pending JP2025118943A (ja) | 2020-03-27 | 2025-05-20 | ２－［（４－｛６－［（４－シアノ－２－フルオロベンジル）オキシ］ピリジン－２－イル｝ピペリジン－１－イル）メチル］－１－［（２ｓ）－オキセタン－２－イルメチル］－１ｈ－ベンゾイミダゾール－６－カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230201185A1 (enExample) |
| EP (2) | EP4537816A3 (enExample) |
| JP (2) | JP2021155415A (enExample) |
| KR (1) | KR20220157486A (enExample) |
| CN (1) | CN115348863A (enExample) |
| AU (1) | AU2021244918A1 (enExample) |
| BR (1) | BR112022017578A2 (enExample) |
| CA (1) | CA3176569A1 (enExample) |
| ES (1) | ES3031577T3 (enExample) |
| IL (1) | IL296694A (enExample) |
| MX (1) | MX2022010811A (enExample) |
| TW (1) | TWI823072B (enExample) |
| WO (1) | WO2021191812A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| EP4048664A1 (en) | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| PL4097097T3 (pl) | 2020-01-29 | 2025-05-12 | Gilead Sciences, Inc. | Związki modulujące glp-1r |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| AU2022263410B2 (en) | 2021-04-21 | 2024-08-01 | Gilead Sciences, Inc. | Carboxy-benzimidazole glp-1r modulating compounds |
| EP4422745A1 (en) | 2021-10-25 | 2024-09-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20250036254A (ko) * | 2022-07-22 | 2025-03-13 | 화이자 인코포레이티드 | 2-[(4-｛6-[(4-시아노-2-플루오로벤질)옥시]피리딘-2-일}피페리딘-1-일｝메틸]-1-[(2s)-옥세탄-2-일메틸]-1h-벤즈이미다졸-6-카복실산,1,3-다이하이드록시-2-(하이드록시메틸)프로판-2-아민 염의 제조를 위한 방법 및 중간체 |
| EP4568664A1 (en) | 2023-04-07 | 2025-06-18 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating a liver disorder or a cardiometabolic disease |
| CN116675680B (zh) * | 2023-08-02 | 2023-10-20 | 药康众拓(北京)医药科技有限公司 | 一种氘代化合物及其制备方法、药物和应用 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025224648A1 (en) * | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| RU2283104C2 (ru) * | 2000-10-24 | 2006-09-10 | Адзиномото Ко., Инк. | Гидрофильный фармацевтический препарат, содержащий натеглинид |
| CH702192A1 (de) | 2009-11-04 | 2011-05-13 | New Dent Ag | Keramisches Implantat. |
| PT2621493T (pt) | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| TWI538748B (zh) * | 2011-11-16 | 2016-06-21 | 鴻海精密工業股份有限公司 | 鏡頭除塵裝置 |
| WO2013117963A1 (en) * | 2012-02-09 | 2013-08-15 | Piramal Enterprises Limited | Stable oral tablet dosage form of an antidiabetic compound |
| KR102444494B1 (ko) * | 2014-01-09 | 2022-09-20 | 베라스템, 인코포레이티드 | 비정상적 세포 성장의 치료를 위한 조성물 및 방법 |
| JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
| RU2696269C1 (ru) | 2015-12-29 | 2019-08-01 | Пфайзер Инк. | Замещенные 3-азабицикло[3.1.0]гексаны в качестве ингибиторов кетогексокиназы |
| MX2018011696A (es) * | 2016-03-31 | 2019-06-06 | Lupin Ltd | Composición farmacéutica de dapagliflozina. |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| CN106271089B (zh) | 2016-09-30 | 2019-01-25 | 英诺激光科技股份有限公司 | 一种激光薄膜刻蚀装置及方法 |
| EA037318B1 (ru) * | 2016-12-16 | 2021-03-11 | Пфайзер Инк. | Агонисты рецептора glp-1 и их применение |
-
2021
- 2021-03-24 WO PCT/IB2021/052430 patent/WO2021191812A1/en not_active Ceased
- 2021-03-24 CA CA3176569A patent/CA3176569A1/en active Pending
- 2021-03-24 TW TW110110639A patent/TWI823072B/zh not_active IP Right Cessation
- 2021-03-24 EP EP24223164.5A patent/EP4537816A3/en active Pending
- 2021-03-24 CN CN202180024485.6A patent/CN115348863A/zh active Pending
- 2021-03-24 EP EP21714685.1A patent/EP4125896B1/en active Active
- 2021-03-24 ES ES21714685T patent/ES3031577T3/es active Active
- 2021-03-24 KR KR1020227036905A patent/KR20220157486A/ko not_active Withdrawn
- 2021-03-24 AU AU2021244918A patent/AU2021244918A1/en not_active Abandoned
- 2021-03-24 US US17/906,651 patent/US20230201185A1/en active Pending
- 2021-03-24 JP JP2021049350A patent/JP2021155415A/ja active Pending
- 2021-03-24 IL IL296694A patent/IL296694A/en unknown
- 2021-03-24 BR BR112022017578A patent/BR112022017578A2/pt not_active Application Discontinuation
- 2021-03-24 MX MX2022010811A patent/MX2022010811A/es unknown
-
2025
- 2025-05-20 JP JP2025083688A patent/JP2025118943A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021155415A5 (enExample) | ||
| MX2022010811A (es) | Tratamiento de la diabetes tipo 2 u obesidad o sobrepeso con el acido 2-[(4-{6-[(4-ciano-2-fluorobencil)oxi]piridin-2-il}piperidin -1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-bencimidazol-6-carboxil ico o una sal farmaceutica del mismo. | |
| RU2011123876A (ru) | Антисмысловые композиции и способы их получения и применения | |
| IL275982B1 (en) | Pharmaceutical compositions for treating cystic fibrosis | |
| HRP20250257T1 (hr) | Farmaceutska kombinacija, pripravak i kombinirana priprema koja sadrži aktivator glukokinaze i inhibitor sglt-2 te metode pripreme i njihova uporaba | |
| JP2020508338A5 (enExample) | ||
| JP2008515905A5 (enExample) | ||
| US20140235558A1 (en) | Pharmaceutical composition having activity of anticancer | |
| WO2004030700A1 (ja) | 固形製剤 | |
| CA2483597A1 (en) | New pharmaceutical compositions containing flibanserin polymorph a | |
| JP2016512234A (ja) | 薬学的複合製剤 | |
| JP2019523258A (ja) | エソメプラゾール、又は薬学的に許容可能なその塩を含むｐＨ依存性薬物放出特性が改善した剤形 | |
| JP4786127B2 (ja) | 色素沈着改善治療薬 | |
| WO2010009619A1 (zh) | 用于治疗高血压和代谢综合症的药物组合物及其应用 | |
| KR101497354B1 (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| CN103800336A (zh) | 一种具有抗血栓活性药物的组合物 | |
| TWI351957B (en) | Prolonged-release diuretic compositions | |
| WO2011141419A1 (en) | Association of the xanthine oxidase inhibitor febuxostat and metformin and use thereof | |
| JPWO2022031666A5 (enExample) | ||
| JP2016505628A (ja) | ２−アミノエタンスルホン酸との組み合わせ | |
| KR20090107960A (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| KR20190107838A (ko) | 이바브라딘의 서방성 약제학적 조성물 및 이의 제조방법 | |
| CN102652747B (zh) | 一种用于治疗高血压的复方药物组合物 | |
| KR20170032681A (ko) | 약제학적 복합제제 | |
| CN105853419B (zh) | 一种用于胃溃疡治疗的药物组合物及其应用 |